

Special Issue

Alzheimer's Disease and Mild Cognitive Impairment: Emerging Therapeutic Targets and Treatment Strategies

Message from the Guest Editors

Alzheimer's disease (AD) is the most common type of neurodegenerative disorder, characterized by progressive impairment of memory and other cognitive functions. AD is preceded by mild cognitive impairment (MCI), a transitional state between normal aging and AD, which is an early warning signal of the pathology. The scope of this Special Issue includes the recent advances in therapeutic targets as well as new pharmaceutical formulations and drug delivery systems for the treatment of AD and MCI. We also welcome publications that clarify and update the state-of-art of the mechanisms that underlie both pathologies. Translational investigations from both non-clinical and clinical approaches would be of great significance.

- Alzheimer's disease
- mild cognitive impairment
- pharmacokinetics
- pharmacodynamics
- drug formulations
- brain delivery
- dendritic spines

Guest Editors

Dr. Ana Fortuna

1. Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
2. Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, Coimbra, Portugal

Dr. Miren Ettcheto Arriola

1. Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain
2. Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain
3. Institute of Neuroscience, University of Barcelona, Barcelona, Spain

Deadline for manuscript submissions

closed (30 June 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/128104

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).